Prescription peptides
LongevityDog · CatTier B

NAD+

Nicotinamide adenine dinucleotide. Cellular energy. Healthy aging. Cats and dogs.

Weight
663 Da
Half-life
Under 30 minutes IV
Type
Coenzyme. Not a peptide.
Studies
17 referenced. 2024 canine RCT.

Prescribe in the platform

Doses are calculated per patient, by weight, in mcg, mL, and syringe units at the compounding partner’s vial strength.

Screen first

Standard screening

Overview

NAD+ is the universal metabolic coenzyme. Central to sirtuin activation, DNA repair, and mitochondrial energy production. Tissue NAD+ pools decline with age across every mammalian species studied.

Simon et al. 2024 ran a randomized controlled trial of a senolytic and NAD+ precursor combination given by mouth to senior dogs, and owner rated cognition improved at the full dose. It tested an oral combination, not injectable NAD+.

Mechanism of action

  1. 01Cofactor for over 500 enzymatic reactions.
  2. 02Powers sirtuin deacetylation activity for genome stability.
  3. 03Substrate for PARP-mediated DNA repair.
  4. 04Central to mitochondrial electron transport and ATP production.
  5. 05Regulates CD38 immune signaling.

Molecular data

PropertyValue
Molecular weight663 Da
TypeCoenzyme
RouteSubcutaneous injection

Species

Dog

Simon 2024 canine RCT of nicotinamide riboside in aged dogs. Improvements in health biomarkers documented. Injectable NAD+ mirrors the mechanism at higher tissue delivery.

Cat

Feline extrapolation from human and canine data. Age-related mitochondrial decline documented across species.

Prescribing indications

  • LongevityPrimary useAge-related mitochondrial dysfunction in senior dogs and cats.
  • NeurologicSupportedCognitive dysfunction syndrome adjunct.
  • RecoverySupportedPost-anesthesia neurologic support in senior patients.
  • RenalEmergingAdjunct in chronic kidney disease.

Dosing and administration

Starting, maintenance, and loading doses are calculated in the platform for the patient’s weight band, at the vial strength our compounding partner dispenses, and drawn to U-100 syringe units for the client’s dosing card. Any override is logged with your initials.

See the worked dose example

Screening and safety

Screen first

Standard screening

Follow up

CCDR for cognition in dogs, plus activity and appetite. Measure at baseline and recheck at 4 to 6 weeks with the same measure.

References

This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.